9 Meters Biopharma (9 Meters Biopharma) Total Inventories : $0.00 Mil (As of Mar. 2023)

View and export this data going back to 2016. Start your Free Trial

What is 9 Meters Biopharma Total Inventories?

9 Meters Biopharma's total inventories for the quarter that ended in Mar. 2023 was $0.00 Mil. 9 Meters Biopharma's average total inventories from the quarter that ended in Dec. 2022 to the quarter that ended in Mar. 2023 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. 9 Meters Biopharma's Net-Net Working Capital per share for the quarter that ended in Mar. 2023 was $-0.60.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

9 Meters Biopharma Total Inventories Historical Data

The historical data trend for 9 Meters Biopharma's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

9 Meters Biopharma Total Inventories Chart

9 Meters Biopharma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Inventories

Get a 7-Day Free Trial

9 Meters Biopharma Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Total Inventories	Get a 7-Day Free Trial															-	-	-	-	-

9 Meters Biopharma Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

9 Meters Biopharma (OTCPK:NMTRQ) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

9 Meters Biopharma's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2023 is

	Net-Net Working Capital Per Share (Q: Mar. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(6.939	+	0.75 * 0	+	0.5 * 0	-	15.612
-	0	-	0)	/	14.3364
=	-0.60

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

9 Meters Biopharma's Days Inventory for the three months ended in Mar. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2023 )	/	Cost of Goods Sold (Q: Mar. 2023 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

9 Meters Biopharma's Inventory Turnover for the quarter that ended in Mar. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2023 )	/	Average Total Inventories (Q: Mar. 2023 )
	=	0	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

9 Meters Biopharma's Inventory to Revenue for the quarter that ended in Mar. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2023 )	/	Revenue (Q: Mar. 2023 )
	=	0	/	0
	=

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

9 Meters Biopharma Total Inventories Related Terms

Thank you for viewing the detailed overview of 9 Meters Biopharma's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

9 Meters Biopharma (9 Meters Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 9 Meters Biopharma Inc (OTCPK:NMTRQ) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

4509 Creedmoor Road, Suite 201, Raleigh, NC, USA, 27612

Website

https://www.9meters.com

9 Meters Biopharma Inc is a clinical-stage biopharmaceutical company focused on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. Its products include NM-002, Larazotide, NM-003, and others.

Executives

Bethany Sensenig	officer: Chief Financial Officer	C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
John Temperato	director, officer: Chief Executive Officer	C/O MELINTA THERAPEUTICS,INC., 300 GEORGE STREET, SUITE 301, NEW HAVEN CT 06511
Mark A Sirgo	director	C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Michael T. Constantino	director	C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Samantha Ventimiglia	director	C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Edward J Sitar	officer: Chief Financial Officer	39 FLAMING ARROW ROAD, MAHWAH NJ 07430
Orbimed Israel Biofund Gp Limited Partnership	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629
Yehuda Michael Rice	director	155 WALNUT STREET, ENGLEWOOD NJ 07631
Nissim Darvish	director, 10 percent owner	C/O INNOVATE BIOPHARMACEUTICALS, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Orbimed Israel Gp Ltd.	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629
Sandeep Laumas	director, officer: Executive Chairman	8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Jay P. Madan	director, officer: President	8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Roy Proujansky	director	144 PAU NEL DRIVE, LANDENBERG PA 19350
Christopher P. Prior	director, officer: Chief Executive Officer	8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
June Sherie Almenoff	officer: COO and Chief Medical Officer	C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019